Comparative osmolarity changes shown in patients with glaucoma eye drops and healthy controls
Session Details
Session Title: Presented Poster Session: Glaucoma and Imaging
Venue: Poster Village: Pod 3
First Author: : J.Paz Moreno-Arrones SPAIN
Co Author(s): : D. Ferrari M. Castejon Cervero M. Teus
Abstract Details
Purpose:
The purpose of this study was to evaluate, at differents cutoff levels, for tear film osmolarity in patients with no symtoms of discomfort suffering from glaucoma or ocular hypertension treated with intraocular pressure (IOP)-lowering medication and compare it with healthy controls.
Setting:
University Hospital Principe De Asturias
Methods:
Cross-sectional study. We enrolled healthy non-glaucomatous age-matched with glaucoma or ocular hypertension patients under treatment with chronically topical antiglaucomatous eyedrops and artificial tears for at least one month.
Neither group of patients reported ocular discomfort. Tear film osmolarity was measured with the TearLab Osmolarity System (TearLab Corp, San Diego, CA), and results were compared between both groups, at differents cutoff levels (308, 312 and 316 mOsm/L). Exclusion criteria included prior ocular surgery in the last six months. Study endpoint was tear film osmolarity.
Results:
74 patients enrolled, 24 in glaucoma group and 50 in control group. A significantly higher mean tear film osmolarity was observed in glaucoma group: 305,44±15,37 versus 318,16± 13,05 mOsm/L (p=0.007). At 308 mOsm/L cutoff level 23 patients (46%) in control group had hyperosmolar tear film versus 19 patients (79%) in glaucoma group (p=0,0001). At 312 mOsm/L cutoff level 14 patients (28%) in control group had hyperosmolar tear film versus 16 patients (66,6%) in glaucoma group (p=0,0001). At 316 mOsm/L cutoff level 8 patients (16%) in control group had hyperosmolar tear film versus 14 patients (58,3%) glaucoma group (p=0,0002).
Conclusions:
Patients treated with IOP-lowering medication exhibit tear film hyperosmolarity despite of artificial tears medication in comparison with a control healthy group. Nevertheless they do not report symptoms of ocular discomfort.
Financial Disclosure:
NONE
